ArticleJournal of cancer research and clinical oncology2023
Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030.
Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Population Dynamic Projections of Near Vision Loss and Refractive Disorders in China and the G20 From 1990 to 2038.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Publication Characteristics and Reporting Quality of GBD-Derived Burden of Disease Studies: A Cross-Sectional Analysis of Lung Cancer.Journal of evidence-based medicine · 2026Article
- Article
- Schisantherin A induces ferroptosis in non‑small cell lung cancer through activation of the YAP/ACSL4/TfR signaling pathway.Molecular medicine reports · 2026Article
- Prevalence and associated factors of cognitive frailty in older patients with lung cancer undergoing chemotherapy: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Global, regional, and national burden of maternal hypertensive disorder: 1990-2021 analysis and future projections.BMC public health · 2025Article
- Cost-effectiveness of low-dose CT screening for non-smokers with a first-degree relative history of lung cancer.BMC public health · 2025Article
- Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model.Frontiers in pharmacology · 2025Article
- Trends and projections of smoking-attributable lung cancer burden among the elderly in China, 1990-2021.American journal of cancer research · 2025Article
- Evolving landscape of female cancers along with attributable risk factors in China from 1990 to 2021, and projections to 2040.Frontiers in public health · 2025Article
- Burden of drug use disorders from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study.Frontiers in pharmacology · 2025Article
- Article
- Trends in Cancer Incidence and Potential Associated Factors in China.JAMA network open · 2024Article
- Burden of malignant mesothelioma in China during 1990-2019 and the projections through 2029.Journal of the National Cancer Center · 2024Article
- Trends and projection of burden on lung cancer and risk factors in China from 1990 to 2060.Thoracic cancer · 2024Article
- Screening for lung cancer using thin-slice low-dose computed tomography in southwestern China: a population-based real-world study.Thoracic cancer · 2024Article
- Burden of drug use disorders in the United States from 1990 to 2021 and its projection until 2035: results from the GBD study.BMC public health · 2024Article
- Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinomaPeerJ · 2024Article
- A Synthesizing Semantic Characteristics Lung Nodules Classification Method Based on 3D Convolutional Neural Network.Bioengineering (Basel, Switzerland) · 2023Article
- Epidemiological Trends of Kidney Cancer Along with Attributable Risk Factors in China from 1990 to 2019 and Its Projections Until 2030: An Analysis of the Global Burden of Disease Study 2019.Clinical epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to identify and project the epidemiological trends and the burden of lung cancer in China.
methodsWe extracted incidence, mortality, disability-adjusted life-years (DALYs) and age-standardized rates of lung cancer in China, between 1990 and 2019, from the Global Burden of Disease Study (2019). The estimated annual percentage change (EAPC) was applied to quantify the trends of lung cancer burden. Furthermore, we used the Bayesian age-period-cohort model to project the incidence and mortality in the next decade.
resultsFrom 1990 to 2019, the estimated national number of lung cancer incident cases increased by 224.0% to 832,920, deaths increased by 195.4% to 757,170 and DALYs increased by 146.1% to 17,128,580, respectively. Meanwhile, the ASIR, ASMR and ASDR showed an upward trend (EAPC of 1.33, 0.94 and 0.42, respectively). The ASIR and ASMR among males were about 2 times more than females, but the increase in ASIR in females (EAPC = 2.24) was more obvious than those in males (EAPC = 0.10) from 2020 to 2030. In China, smoking remained responsible for the highest burden of lung cancer, but the contribution of ambient particulate matter pollution to DALYs increased from 10.6% in 1990 to 22.5% in 2019 in total population. Moreover, we predicted that the number of deaths from lung cancer will increase by 42.7% in China by 2030.
conclusionIn China, the burden of lung cancer has been increasing over the past three decades, which highlights more targeted intervention measures are needed to reduce the burden of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.